CD274 and neoplasm: In TMAs, no (0/28) DDLPS cases showed immunoreactivity with the PD-L1 (22C3) antibody, and one (1/29) DDLPS case showed immunoreactivity with PD-L1 (SP142) antibody in ≥ 1% of tumor cells.